

DAFTAR PUSTAKA

1. Kemenkes. Pedoman Pencegahan dan Pengendalian Coronavirus Diseases (COVID-19). 13 Juli 20. 1-214 hal.
2. Chen F fang, Zhong M, Liu Y, Zhang Y, Zhang K, Su D zhen, et al. *The characteristics and outcomes of 681 severe cases with COVID-19 in China*. J Crit Care. 2020;60:32–7.
3. Messina G, Polito R, Monda V, Cipolloni L, Nunno N Di, Mizio G Di, et al. *Functional Role of Dietary Intervention to Improve the Outcome of COVID-19 : A Hypothesis of Work*. 2020;(December 2019).
4. Ortiz-prado E, Simbaña-rivera K, Barreno LG-, Rubio-neira M, Guaman LP, Kyriakidis NC, et al. *Clinical , molecular , and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review*. *Diagnostic Microbiol Infect Dis [Internet]*. 2020;98(1):115094. Tersedia pada: <https://doi.org/10.1016/j.diagmicrobio.2020.115094>
5. Bohn MK, Hall A, Sepiashvili L, Jung B, Steele S, Adeli K. *Pathophysiology of COVID-19 : Mechanisms Underlying Disease Severity and Progression*. 2020;(89):288–301.
6. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. *Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan , China*. 2020;2019:4–10.
7. Yang L, Liu S, Liu J, Zhang Z, Wan X, Huang B, et al. *COVID-19 : immunopathogenesis and Immunotherapeutics*. *Signal Transduct Target Ther [Internet]*. 2020;(July):1–8. Tersedia pada: <http://dx.doi.org/10.1038/s41392-020-00243-2>
8. Zhu Z, Cai T, Fan L, Lou K, Hua X, Huang Z, et al. *Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019*. *Int J Infect Dis [Internet]*. 2020;95:332–9. Tersedia pada: <https://doi.org/10.1016/j.ijid.2020.04.041>
9. Kemenkes RI. Situasi terkini perkembangan Novel Coronavirus (COVID-19) 22 Oktober 2020 [Internet]. Tersedia pada: <https://infeksiemerging.kemkes.go.id/document/Situasi-Terkini-Perkembangan-COVID-19-23-Oktober-2020-1156/view>
10. Infeksi Emerging Kementerian Kesehatan Republik Indonesia [Internet]. 2020. Tersedia pada: <https://infeksiemerging.kemkes.go.id/> diakses tanggal 19 Oktober 2020
11. Kementerian Kesehatan Republik Indonesia. Petunjuk Teknis Pelaksanaan Vaksinasi Dalam Rangka Penanggulangan Pandemi Corona Virus Disease 2019

- (COVID-19). Keputusan Direktur Jenderal Pencegah dan Pengendali Penyakit. 2021;NOMOR HK.0.
12. CNN Indonesia. 2020. Biaya perawatan COVID-19. Tersedia pada: <https://www.cnnindonesia.com/ekonomi/20201116172304-532-570474/rata-rata-biaya-perawatan-covid-19-rp184-juta-per-orang>. diakses tanggal 25 Desember 2020
 13. Abbasifard M, Khorramdelazad H. *The bio-mission of interleukin-6 in the pathogenesis of COVID-19 : A brief look at potential therapeutic tactics. Life Sci [Internet]. 2020;257(June):118097.* Tersedia pada: <https://doi.org/10.1016/j.lfs.2020.118097>
 14. World Health Organization. 2020. *Modes of transmission of virus causing COVID-19 : implications for IPC precaution recommendations.* 2020;(March):1–3.
 15. World Health Organization. 2020. *Transmission of SARS-CoV-2: implications for infection prevention precautions [Internet].* Tersedia pada: <https://www.who.int/news-room/commentaries/detail/>
 16. Satici C, Asim M, Sargin E, Gursoy B, Alkan M, Kamat S, et al. *International Journal of Infectious Diseases Performance of pneumonia severity index and CURB-65 in predicting 30-day mortality in patients with COVID-19. Int J Infect Dis [Internet]. 2020;98:84–9.* Tersedia pada: <https://doi.org/10.1016/j.ijid.2020.06.038>
 17. Tufan A, Aslihan, Marco. *COVID-19 , immune system response , hyperinflammation and repurposing antirheumatic drugs.* Turkish J Med Sci. 2020;50(March):620–32.
 18. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J. *Risk factors of critical & mortal COVID-19 cases : A systematic literature review and meta-analysis. J Infect. 2020;81(January):e16–25.*
 19. Pelaia C, Tinello C, Vatrella A, Sarro G De. *Lung under attack by COVID-19-induced cytokine storm : pathogenic mechanisms and therapeutic implications.* 2020;1–9.
 20. Machhi J, Herskovitz J, Senan AM, Dutta D, Nath B, Oleynikov MD, et al. *The Natural History , Pathobiology , and Clinical Manifestations of SARS-CoV-2 Infections.* 2020;
 21. Kordzadeh-kermani E, Khalili H, Karimzadeh I, Scholar G. *Pathogenesis , clinical manifestations and complications of coronavirus disease 2019.* 2020;2019.
 22. Barrett D. *IL-6 Blockade in Cytokine Storm Syndromes.* 2019;6.
 23. Gupta KK, Khan MA, Singh SK. *Constitutive Inflammatory Cytokine Storm: A Major Threat to Human Health. J Interf Cytokine Res.* 2020;40(1):1–5.
 24. Aziz M, Fatima R, Assaly R. *Elevated interleukin - 6 and severe COVID - 19 : A meta - analysis. J Med Virol.* 2020;1–3.

25. Huang L, Zhao X, Qi Y, Li H, Ye G, Liu Y, et al. *Sepsis-associated severe interleukin-6 storm in critical coronavirus disease 2019*. 2020;(1).
26. Wang L. *C-reactive protein levels in the early stage of COVID-19*. *Med Mal Infect [Internet]*. 2020;50(4):332–4. Tersedia pada: <https://doi.org/10.1016/j.medmal.2020.03.007>
27. Ayanian S. *The association between biomarkers and clinical outcomes in novel coronavirus pneumonia in a US cohort*. 2020;
28. Herold T, Jurinovic V, Arnreich C, Lipworth BJ. *Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19*. *J Allergy Clin Immunol [Internet]*. 2020;146(1):128–136.e4. Tersedia pada: <https://doi.org/10.1016/j.jaci.2020.05.008>
29. Pacheco JM, Smoliga GR, Donnell VO, Brito BP, Stenfeldt C, Rodriguez LL, et al. *Persistent Foot-and-Mouth Disease Virus Infection in the Nasopharynx of Cattle ; Tissue-Specific Distribution and Local Cytokine Expression*. 2015;1–20.
30. Feng X, Li S, Sun Q, Zhu J, Chen B. *Immune-Inflammatory Parameters in COVID-19 Cases : A Systematic Review and Meta-Analysis*. 2020;(June).
31. Saus PS, Hanafy DA, Barrack R. *Case Report Editorial*. *Indones J Cardiol*. 2020;41(2):49–53.
32. Lima R De, Sanyasi R, Pramudita EA. *Ischemic stroke in coronavirus disease 19 (COVID-19) positive patient : a case report*. *J Med Sci*. 2020;52(3):166–72.
33. Azwar MK, Kirana F, Kurniawan A, Handayani S. *Gastrointestinal Presentation in COVID-19 in Indonesia : A Case Report*. *Acta Med Indones*. 2019;52(1):63–7.
34. Azmi NU, Puteri MU, Lukmanto D. *Cytokine Storm in COVID-19 : An Overview , Mechanism , Treatment Strategies , and Stem Cell Therapy Perspective*. *Pharm Sci Res*. 2020;7(June):1–11.
35. Fajgenbaum DC, H.June C. *Cytokine Storm*. *N Engl J Med*. 2020;383:2255–73.
36. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. *Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia*. *N Engl J Med*. 2020;382(13):1199–207.
37. *World Health Organization. Weekly Operational Update on COVID-19 september 27, 2020*. *World Heal Organ*. 2020;(October):1–10.
38. Riadi A. *Pedoman dan Pencegahan Coronavirus (COVID- 19)*. *Math Didact J Pendidik Mat*. 2019;4:1–214.
39. Surveillances V. *The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China , 2020*. 2020;2(8):113–22.

40. Kumar M, Khodor S Al. *Pathophysiology and treatment strategies for COVID - 19. J Transl Med* [Internet]. 2020;1–9. Tersedia pada: <https://doi.org/10.1186/s12967-020-02520-8>
41. Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. *Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci* [Internet]. 2020;0(0):1–11. Tersedia pada: <https://doi.org/10.1080/10408363.2020.1770685>
42. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. *Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19) A Review. 2020;2019:1–13.*
43. *Duration of Isolation and Precautions for Adults with COVID, Centers for Disease Control and Prevention Website. Updated Oct. 19, 2020. diakses tanggal 6 November 2020.* <https://www.cdc.gov/coronavirus/2019-ncov/community/strategy-discontinue-isolation.html>.
44. Adnan M, Khan S, Kazmi A, Bashir N, Siddique R. *COVID-19 infection : Origin , transmission , and characteristics of human coronaviruses. J Adv Res.* 2020;24:91–8.
45. Yuki K, Fujiogi M, Koutsogiannaki S. *COVID-19 pathophysiology : A review. 2020;(January).*
46. Saxena SK. *Coronavirus Disease 2019. Epidemiology, Pathogenesis, Diagnosis, and Therapeutics. Vol. 2019.* Springer India; 2019.
47. Bergman CC, Silverman RH. *COVID-19 : Coronavirus replication , pathogenesis , and therapeutic strategies. 2020;(June):321–7.*
48. Erener S. *DIABETES , INFECTION RISK AND COVID-19. Mol Metab* [Internet]. 2020;101044. Tersedia pada: <https://doi.org/10.1016/j.molmet.2020.101044>
49. Moenadjat Y. *Minireview : Covid – 19 : Criticism of The Pathogenesis Based on The Tropism Minireview : Covid – 19 : Criticism of The Pathogenesis Based on The Tropism. 2020;5(1).*
50. Li X, Geng M, Peng Y, Meng L, Lu S. *Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal* [Internet]. 2020;10(2):102–8. Tersedia pada: <https://doi.org/10.1016/j.jpha.2020.03.001>
51. Parasher A. *COVID-19 : Current understanding of its pathophysiology , clinical presentation and treatment. 2020;1–9.*
52. Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S. *Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol.* 2020;39(7):2085–94.

53. Dhama K, Kumar S, Pathak M, Iqbal M, Tiwari R, Bonilla-aldana DK, et al. *An update on SARS-CoV-2 / COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies. Travel Med Infect Dis* [Internet]. 2020;(March):101755. Tersedia pada: <https://doi.org/10.1016/j.tmaid.2020.101755>
54. Lu L, Zhang H, Zhan M, Jiang J, Yin H, Dauphars DJ. *Preventing Mortality in COVID-19 Patients: Which Cytokine to Target in a Raging Storm?* 2020;8(July):1–8.
55. Soy M, Tabak F, Kayhan S. *Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment.* 2020;
56. Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. *Cytokine and Growth Factor Reviews The cytokine storm in COVID-19: An overview of the involvement of the chemokine / chemokine-receptor system.* *Cytokine Growth Factor Rev* [Internet]. 2020;53(May):25–32. Tersedia pada: <https://doi.org/10.1016/j.cytogfr.2020.05.003>
57. Azer SA. *COVID-19: pathophysiology, diagnosis, complications and investigational therapeutics.* *New Microbes New Infect* [Internet]. 2020;37(M):100738. Tersedia pada: <https://doi.org/10.1016/j.nmni.2020.100738>
58. PDPI, PERKI, PAPDI, PERDATIN, IDAI. PEDOMAN TATALAKSANA COVID-19 EDISI 2. 2020.
59. Kusumaningrum W. Peran Interleukin-6 dalam menentukan keluaran 'Modified Rankin Scale pada sirkulasi parsial anterior stroke iskemik akut. Universitas Indonesia; 2014.
60. Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, et al. *Detectable serum SARS-CoV-2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients.* *Clin Infect Dis.* 2020;(Xx Xxxx):13–5.
61. Zhang J, Hao Y, Ou W, Ming F, Liang G, Qian Y, et al. *Serum interleukin - 6 is an indicator for severity in 901 patients with SARS - CoV - 2 infection: a cohort study.* *J Transl Med* [Internet]. 2020;1–8. Tersedia pada: <https://doi.org/10.1186/s12967-020-02571-x>
62. Susantiningsih T, Mustofa S. Ekspresi IL-6 dan TNF- α Pada Obesitas IL-6 and TNF- α Expression in Obesity. *J Kedokt UNILA.* 2018;2:174–80.
63. Yan Y, Liu M, Li X, Deng X, Jin Y, Qin Q, et al. *Utility of the neutrophil-to-lymphocyte ratio and C- reactive protein level for coronavirus disease 2019.* *Scand J Clin Lab Invest* [Internet]. 2020;0(0):1–5. Tersedia pada: <https://doi.org/10.1080/0036513.2020.1803587>
64. Idhayu AT, Kedokteran F, Indonesia U, Studi P, Penyakit I. Perbedaan Kadar C-Reactive Protein Pada Demam Akut Karena Infeksi Dengue dengan Demam Tifoid. 2014;

65. Udwardia ZF, Tripathi AR, Nanda VJ, Joshi SR. *Prognostic Factors for Adverse Outcomes in COVID* [Internet]. diakses tanggal 16 Desember 2020; 2020. Tersedia pada: <https://www.japi.org/w2f4d4a4/prognostic-factors-for-adverse-outcomes-in-covid-19-infection>
66. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. *Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan , China : a descriptive study. Lancet [Internet].* 2020;6736(20):1–7. Tersedia pada: [http://dx.doi.org/10.1016/S0140-6736\(20\)30211-7](http://dx.doi.org/10.1016/S0140-6736(20)30211-7)
67. Shastri A, Wheat J, Agrawal S. *Delayed clearance of SARS-CoV2 in male compared to female patients: High ACE2 expression in testes suggests possible existence of gender-specific viral reservoirs.* medRxiv.
68. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q. *Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2 : a systematic review and meta-analysis. Int J Infect Dis.* 2020;94(January):91–5.
69. Lighter J, Philips M, Sarah Hochman. *Obesity in Patients Younger than 60 years is a risk factor for Covid-19 hospital admission. Infect Dis Soc Am.* 2020;
70. Singh H, Choudhari R, Nema V, Arif A. *Microbial Pathogenesis ACE2 and TMPRSS2 polymorphisms in various diseases with special reference to its impact on COVID-19 disease.* 2020;(January).
71. Devaux CA, Rolain J, Raoult D. *ACE2 receptor polymorphism : Susceptibility to SARS-CoV-2 , hypertension , multi-organ failure , and COVID-19 disease outcome.* 2020;(January).
72. Innammorato M, Pasquariello L, Pizzirusso D, Guerrieri G, Castelli S, Pezzuto A. *Age is not the only risk factor in COVID-19 : the role of comorbidities and of long staying in residential care homes.* 2021;1–10.
73. Goujon A, Natale F, Ghio D, Conte A. *Age , gender , and territory of COVID-19 infections and fatalities.* 2020.
74. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. *Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan , China : a retrospective cohort study. Lancet [Internet].* 2020;395(10229):1054–62. Tersedia pada: [http://dx.doi.org/10.1016/S0140-6736\(20\)30566-3](http://dx.doi.org/10.1016/S0140-6736(20)30566-3)
75. Jurado A, Martín MC, Abad-molina C, Orduña A, Martínez A, Ocaña E, et al. *protein , and lymphocytes as key clues from a multicentre retrospective study.* 2020;1–15.
76. Gagliardi MC, Tieri P, Ortona E. *ACE2 expression and sex disparity in COVID-19. Cell Death Discov [Internet].* 2020;1–2. Tersedia pada: <http://dx.doi.org/10.1038/s41420-020-0276-1>
77. Bwire GM. *Coronavirus : Why Men are More Vulnerable to Covid-19 Than Women ? Top Collect Covid-19.* 2020;8–10.

78. Sorour K, Sarhan H, El-menshawy H. *ACE-2 in the highlight of COVID-19 A proposed pathology and potential correlations.*
79. Peckham H, Gruijter NM De, Ciurtin C, Wedderburn LR, Deakin CT, Raine C, et al. *Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ICU admission. Nat Commun [Internet].* 2020;1–10. Tersedia pada: <http://dx.doi.org/10.1038/s41467-020-19741-6>
80. Guan W, Liang W, Zhao Y, Liang H, Chen Z, Li Y, et al. *Comorbidity and its impact on 1590 patients with Covid-19 in China : A Nationwide Analysis.* 2020.
81. Fang H, Liu Q, Xi M, Xiong D, He J, Luo P, et al. *Impact of comorbidities on clinical prognosis in 1280 patients with different types of COVID-19.* 2021;75–85.
82. Abu-farha M, Al-mulla F, Thanaraj TA. *Impact of Diabetes in Patients Diagnosed With COVID-19.* 2020;11(December):1–11.
83. DU Y, Zhou N, Zha W, Lv Y. *Hypertension is a clinically important risk factor for critical illness and mortality in COVID-19: A meta-analysis. Nutr Metab Cardiovasc Dis [Internet].* 2020; Tersedia pada: <https://doi.org/10.1016/j.numecd.2020.12.009>
84. Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P. *Comorbidity and its Impact on Patients with COVID-19.* Top Collect Covid-19. 2020;
85. Rees EM, Nightingale ES, Jafari Y, Waterlow NR, Clifford S, Pearson CAB, et al. *COVID-19 length of hospital stay : a systematic review and data synthesis.* 2020;
86. Anurag A, Jha PK, Kumar A. *Differential white blood cell count in the COVID-19: A cross-sectional study of 148 patients. Diabetes dan Metab Syndr.* 2020;14(January).
87. Sun Y, Zhou J, Ye K. *White blood cells and severe COVID-19: a Mendelian randomization study.* medRxiv. 2020;1–27.
88. Vafadar E, Teimouri A, Rezaee R, Morovatdar N, Foroughian M, Layegh P, et al. *Increased age , neutrophil-to-lymphocyte ratio (NLR) and white blood cells count are associated with higher COVID-19 mortality.* Am J Emerg Med [Internet]. 2021;40:11–4. Tersedia pada: <https://doi.org/10.1016/j.ajem.2020.12.003>
89. Wagner J, Dupont A, Larson S, Cash B, Farooq A. *Absolute lymphocyte count is a prognostic marker in Covid-19 : A retrospective cohort review. Int J Lab Hematol.* 2020;(May):1–5.
90. Farias G De, Kaiser E, Nunes U, Giunchetti IID, Melo IB, Loureiro C, et al. *Imaging findings in COVID-19 pneumonia. Clin Lab Med.* 2020;1–8.
91. Vancheri SG, Savietto G, Ballati F, Maggi A, Canino C, Bortolotto C, et al. *Radiographic findings in 240 patients with COVID-19 pneumonia : time-dependence after the onset of symptoms. Eur Radiol.* 2020;30:6161–9.